2 bullish articles today about Ampio, Optina, Ampion, Zertane, ORP, NCE001, NYSE listing today, 2 pivotal trials for 2 blockbusters underway, an imminent announcement of Zertane licensing deal with BIg Pharma, loads of trial data to come, Optina about to unseat Eylea, Ampion will dominate the $65 billion anti-inflammatory market, and other surprises all in store very soon for AMPE.
What an amazing buying opportunity!!!
Can't say later that everybody hasn't been advised.
This is one of the easiest one decision stocks in decades. . . . Buy . . .and . . .HOLD . . . and become very very wealthy.